1. NO-HDAC dual inhibitors
- Author
-
Negar Omidkhah and Razieh Ghodsi
- Subjects
Pharmacology ,chemistry.chemical_classification ,medicine.drug_class ,Chemistry ,Synthesis methods ,Organic Chemistry ,Histone deacetylase inhibitor ,Cancer ,Antineoplastic Agents ,General Medicine ,Nitric Oxide ,medicine.disease ,Histone Deacetylases ,No donors ,Dual (category theory) ,Histone Deacetylase Inhibitors ,Enzyme ,Drug Discovery ,medicine ,HDAC inhibitor ,Humans ,Heart Hypertrophy ,Drug Screening Assays, Antitumor ,Cell Proliferation - Abstract
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first time in 2013 as an attractive new topic. Here we collected the general structure of all synthesized NO-HDAC dual inhibitors, lead compounds, synthesis methods and biological features of the most potent dual NO-HDAC inhibitor in each category with the intention of assisting in the synthesis and optimization of new drug-like compounds for diverse diseases. Based on studies done so far, NO-HDAC dual inhibitors have displayed satisfactory results against wound healing (3), heart hypertrophy (3), inflammatory, cardiovascular, neuromuscular illnesses (11a-11e) and cancer (6a-6o, 9a-9d, 10a-10d, 16 and 17). NO-HDAC dual inhibitors can have high therapeutic potential for various diseases due to their new properties, NO properties, HDAC inhibitor properties and also due to the effects of NO on HDAC enzymes.
- Published
- 2022
- Full Text
- View/download PDF